Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of AEZS stock opened at $4.41 on Wednesday. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.80. The company has a market cap of $7.89 million, a price-to-earnings ratio of -0.30 and a beta of 1.55. The stock has a 50 day simple moving average of $7.20 and a 200-day simple moving average of $7.59.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.